Clinical trials: High-risk Neuroblastoma
High-Risk Neuroblastoma
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years.
- Trial name
- SHINE (NCT07549321)
- Testing
- hu1418K322A + Temozolomide + Irinotecan
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 144 people
- Sponsor
- Renaissance Pharma Ltd.
Neuroblastoma, High-risk Neuroblastoma
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.
- Conditions
- Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
- Trial name
- NCT06057948
- Testing
- OPT-821 (QS-21), oral β-glucan
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
High Risk Neuroblastoma
Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma
This clinical trial investigates the safety, side effects, and effectiveness of combining an immunotherapy drug called dinutuximab-beta with standard induction chemotherapy for patients newly diagnosed with high-risk…
- Trial name
- NCT07688252
- Testing
- Dinutuximab Beta, Induction chemotherapy
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
High-Risk Neuroblastoma
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
This clinical trial will evaluate the safety of chemoimmunotherapy with Naxitamab and COG-type induction chemotherapy in newly-diagnosed patients with high-risk neuroblastoma. We aim to recruit 10 patients over the next 2 years.
- Trial name
- NCT07537400
- Testing
- Naxitamab
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Shaare Zedek Medical Center
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular
Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma
This phase II trial evaluates whether an investigational scan (18F-MFBG positron emission tomography [PET]/computed tomography [CT] or PET/magnetic resonance imaging [MRI]) can accurately detect tumors in patients with newly…
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, High Risk Neuroblastoma
- Trial name
- NCT06858501
- Testing
- Biospecimen Collection, Computed Tomography, Florbenguane F18
- Sponsor
- Children's Oncology Group
High-risk Neuroblastoma, Neuroblastoma
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
- Conditions
- High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
- Trial name
- NCT06528496
- Testing
- DANYELZA, Sargramostim, Cytoxan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Neuroblastoma, Relapsed Neuroblastoma
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
- Conditions
- Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma
- Trial name
- GPC2 (NCT05650749)
- Testing
- GPC2 CAR T cells
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stephan Grupp MD PhD
Refractory Neuroblastoma, Relapsed Neuroblastoma
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
- Conditions
- Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma
- Trial name
- PHOX2B (NCT07007117)
- Testing
- PHOX2B PC-CAR T Cells
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Stephan Grupp MD PhD
High Risk Neuroblastoma, Recurrent Neuroblastoma
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
This phase I trial is to find out the best dose, possible benefits and/or side effects of magrolimab in combination with dinutuximab in treating patients with neuroblastoma that has come back (relapsed) or does not respond to…
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma
- Trial name
- NCT04751383
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 11 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
High Risk Neuroblastoma
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
This phase III trial is studying the side effects of giving monoclonal antibody Ch14.18 together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in treating patients with neuroblastoma.
- Trial name
- NCT01041638
- Testing
- Aldesleukin, Diagnostic Laboratory Biomarker Analysis, Dinutuximab
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute (NCI)
SCLC, Malignant Melanoma
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA…
- Conditions
- SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
- Trial name
- NCT05130255
- Testing
- GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Y-mAbs Therapeutics
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Ganglioneuroblastoma, High Risk Neuroblastoma
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This phase II pilot trial studies the side effects and how well dinutuximab and sargramostim work when combined with chemotherapy in patients with high-risk neuroblastoma.
- Trial name
- NCT03786783
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
High-risk Neuroblastoma
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL).
- Trial name
- NCT06480526
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed Neuroblastoma, Refractory Neuroblastoma
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
- Trial name
- DUAL-NK-NB (NCT07502287)
- Testing
- EB-DTNB-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
High Risk Neuroblastoma, Recurrent Neuroblastoma
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab work with or without eflornithine in treating patients with neuroblastoma that has come back (relapsed) or that isn't responding to…
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT03794349
- Testing
- Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride
- Where
- 145 sites in United States, Australia and 3 more
- Volunteers
- 94 people
- Sponsor
- Children's Oncology Group
Neuroblastoma, High-risk Neuroblastoma
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income…
- Trial name
- RISE in HR NBL (NCT06831552)
- Testing
- RISE Intervention
- Where
- 6 sites in United States
- Volunteers
- 84 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed Neuroblastoma, Refractory Neuroblastoma
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
This Phase 1/2 trial aims to determine the safety and feasibility of administration of autologous chimeric antigen receptor (CAR) T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor in pediatric subjects with…
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-risk Neuroblastoma
- Trial name
- NCT06803875
- Testing
- Autologous hALK.CAR T cells
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Roberto Chiarle
High Risk Neuroblastoma
Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN）
Evaluate the impact of maintenance therapy with eflornithine on event-free survival and overall survival in high-risk neuroblastoma (NB) children after immunotherapy, and assess its safety.
- Trial name
- CSHEIN (NCT07278674)
- Testing
- Oral administration of eflornithine for the prevention of high-risk neuroblastoma
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Children's Hospital
Very High Risk Neuroblastoma
Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction
The main objective is to evaluate the efficacy of two intensified consolidation strategies in very-high risk neuroblastoma (VHR-NBL) patients in terms of event-free survival from randomisation date.
- Trial name
- VERITAS (NCT03165292)
- Testing
- mIBG, Topotecan, Thiotepa
- Where
- 9 sites in Austria, France and 3 more
- Volunteers
- 34 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris